Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 5Withdrawn 2Recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Meningioma 1Glioblastoma 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × TIC10 compound × Clear all
NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn
CNS

Meningioma

NCT04629209 2023-11-24

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡